EZH2 and small cell lung carcinoma: Furthermore, the effects of synergy between chemotherapies and the enhancer of zeste homolog 2 (EZH2) inhibition on tumor-inhibition of SCLC was demonstrated in PDX models, even in those that were resistant to chemotherapy (28).